News 24.01.2024 Schlieren, Switzerland January 23rd, 2024 – EraCal Therapeutics Ltd. today announced that it has entered into a collaboration and license agreement with Novo Nordisk A/S to develop and commercialize EraCal’s oral, small molecule program. The asset was discovered with EraCal’s platform technology and is believed to target a novel mechanism...
News 17.01.2024 Cologne, Germany and Zürich, Switzerland 16 January 2024 – DISCO Pharmaceuticals (“DISCO”), a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth today. The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed...
News 10.01.2024 Zurich/Schlieren ZH - The city of Zurich is joining the Bio-Technopark Schlieren-Zurich as a member. The innovative strength of the companies and researchers is expected to create sustainable jobs in the Zurich economic region. The City of Zurich will join the Bio-Technopark Schlieren-Zurich as a member, according to a LinkedIn post...
News 08.01.2024 Newton, Mass., USA & Wädenswil, Switzerland, January 5, 2024 — GlycoEra AG, a pioneering company advancing a pipeline of extracellular protein degraders for the treatment of autoimmune disorders, today announced the expansion of its Series A financing with an investment from Bristol Myers Squibb (BMS). BMS joins existing investors, including...
News 08.01.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview...